Ian Frizzels recent vlog about his MP's intervention regarding the prescription for Exanatide inspired this post. I hope he contributes. It's unashamedly selfish. Having tried to establish DIP on first diagnosis, I switched to research for disease modifying "new hopes" after the DATscan.
My dilemma. Do I try for 1,2,3 or none of the "target" drugs. These are Exanatide, Isradipin, and Simvastatin. Ian has clearly concluded that Exanatide is the golden bullet, and it is my favourite by a short head. It's possible indicated benefit would appear to be neuroprotection in early stage PD - although Ian's neurologist (at the trial centre) apparently agrees it would potentially benefit his further progressed condition.
Exanatide, and repurposed drugs were the most promising immediate option, although further research revealed new developments in the microbiome to be interesting (and possibly the most readily accessible)
I mentioned to my French neuroligist I had read about Exanatide and could he prescribe it (we may have had a language issue). His response to my decision to decline Sinemet and look to new disease modifying options was to suggest Rasagiline and refer me to Christine Brefel at Purpan Toulouse. As a result of that I am waiting to join a trial for a monoclonal Asyn antibody. It's France. I'm still waiting. I wrote a letter a week ago. Trial was due to start "by the new year"
I asked my UK GP if he could prescribe drugs I was interested in. He didn't know what the DATscan showed, hadn't heard of Isradipine, and referred me to a neurologist appointment (back in June - appointment January 23rd. I just tried to change it, and next available is June 2019. We have some problems in the NHS)
Exanatide is struggling to get a phase 3 trial going and it will take 5 years for a conclusion.
Isradipin is in phase 3 (completed November 2018) results due 1st quarter 2019. This looks the most likely to actually establish a neuroprotective effect and be the first to get licenced (I hope I haven't jinxed it with commentators curse). Just making it to the end of the trial suggests some positive outcomes. There is recent research, since the trial began, (on mice), which suggests a mechanism for how and why it is working. If its working.
Simvastatin is in phase 3 concluding early 2020. My least favourite - there is confusing research around statins, and I have taken them before and felt sh1t. (although a condition like PD changes my willingness to tolerate side effects)
I have blood pressure between 140/90 and 150/100 depending on how and when you measure. Cholesterol of around 7.5 last blood test.
My French GP will prescribe Isradipine for BP. (and probably Simvastatin if I asked). My UK GP has (gleefully) prescribed Simvastatin (10mg) which I haven't taken yet. He has been trying to get me on statins for years, and I didn't enjoy the experience. The phase 3 trial dose for PD is 80mg which is off the scale for normal cholesterol control
The trial dose of Isradipine is 10mg which again is at the top of the range for BP control
Exanatide I am probably a good candidate for since I have pretty good bowel function, and am a little overweight (88kg 180cm).
Any drug has side effects. A combination of drugs a multitude of interactions. With each other, general physiology, and ... the microbiome. (Interestingly Dr Athuda speculated that it was possible that Exanatides action in PD was effected via microbiome changes, at least in part)
So - mostly I am planning to wait till the January appointment, and see if I can leverage Ian's off-label recommendation for one of my own. I can also probably wait for the Isradipine trial outcome - but maybe take it for BP anyway if side effects are tolerable
I share Ian's view that with a progressive neurodegenerative condition tomorrow is a day too late to start a medication which WILL slow or stop progress.
But when its not clear if any one medication does, several appear to work via different mechanisms, how do you back the right horse? Or know whether to call off the race and back all of them?